CMB International Securities | Equity Research | Company Update

# ZhongAn Online (6060 HK)

### 1H21 UW profitable, Reiterate BUY

Zhong An 1H21 net profit grew by 54% YoY to RMB755mn, tracking 88% of FY21E market consensus. The strong earnings growth was driven by a 4.1ppt improvement in combined ratio and 45% premium growth (vs 1.7% industry growth). The online insurer turned underwriting profitable for the first time since its establishment, with a combined ratio of 99.4% in 1H21. The economies of scale emerge, as Zhong An continues to deliver strong growth in spite of the gloomy market environment. We revise up earnings forecast to reflect better underwriting performance than previously estimated, and raise TP by 4% to HK\$64, based on 3.5x P/S FY21E. Reiterate BUY.

- Turned underwriting profitable for the 1<sup>st</sup> time. Zhong An improved its combined ratio by 4.1ppt YoY to 99.4% in 1H21, while the industry average combined ratio deteriorated to 99.6% amid comprehensive auto insurance reform. The online insurer turned underwriting profitable as the economies of scale emerge. Loss ratio declined by 7.2ppt YoY to 49.4%, as the loss experiences improved across all ecosystems except for auto business. Expense ratio increased by 3.1ppt YoY to 50%, owing to the rebound of high commission travel insurance business and higher customer acquisition costs of consumer finance business.
- Diversified growth drivers. The average premium income per customer grew by 41% YoY to RMB23.8 in 1H21. The online insurer recorded strong premiums growth across all business lines except for auto and shipping return insurance. Digital lifestyle ecosystems delivered 52% premium growth in 1H21, driven by exponential momentum of innovative business as well as a recovery of travel insurance. Pet insurance premiums increased by over 60x YoY, and screen crack insurance grew over 37x YoY. Consumer finance business recorded 192% premiums growth, while the outstanding loan balance increased by only 30% YoY, as the reinsurance rate was up 14ppt YoY to 21.8% in 1H21. Health ecosystem also reported 29% revenue growth, as the number of paid users grew 10% YoY. The strong momentum sustained into 2H, as monthly premiums increased 100% YoY in July.
- Positive progress for technology business. The revenue from technology export increased by 122% YoY to RMB266mn in 1H21, as the pandemic outbreak has necessitated digital transformation of traditional financial institutions and enlarged the addressable market. The online insurer also formed a partnership with AIA in Southeast Asia on digital marketing.

#### Earnings Summary

(YE Dec 31)	FY19A	FY20E	FY21E	FY22E	FY23E
GWP (RMB mn)	14,630	16,709	22,307	26,554	32,683
YoY change (%)	30.0	14.2	33.5	19.0	23.1
Net profit (RMB mn)	(454)	554	975	1,185	1,866
EPS (RMB)	(0.3)	0.4	0.7	0.8	1.3
YoY growth (%)	N.A	N.A	76.0	21.5	57.4
Consensus EPS (RMB)	n.a	1.5	2.0	2.3	2.6
P/E(x)	(93.1)	76.3	43.4	35.7	22.7
P/B (x)	2.6	2.4	2.3	2.1	1.9
ROE (%)	(3.0)	3.6	6.0	6.8	9.8
ROA (%)	(1.6)	1.4	2.4	3.7	7.5
Combined ratio (%)	113.3	102.5	99.7	98.8	98.6

Source: Company data, Bloomberg, CMBIS estimates



### **BUY (Maintain)**

Target Price	HK\$64.00			
(Previous TP	HK\$61.57)			
Up/Downside	+66.2%			
Current Price	HK\$38.50			

#### **China Insurance Sector**

Gigi Chen, CFA (852) 3916 3739 gigichen@cmbi.com.hk

#### Stock Data

Mkt Cap (HK\$ mn)	49,018
Avg 3 mths t/o (HK\$ mn)	282.30
52w High/Low (HK\$)	78.80/32.50
Total Issued Shares (mn)	1,420
Source: Bloomberg	

#### Shareholding Structure

Ant Group	13.54%
Tencent Computer System	10.21%
Ping An Insurance	10.21%
Source: HKEx	

#### Share Performance

	Absolute	Relative
1-mth	-22.2%	-15.5%
3-mth	-16.7%	-5.9%
6-mth	-46.9%	-35.7%
Source: Bloomberg		

#### 12-mth Price Performance



#### Auditor: PwC

#### **Related Reports**

"Transfer of Coverage; 1H21 preview: Worst case already priced in" - 27 Jul 2021



### Figure 1. Zhong An: 1H21 Results Summary

	1H20	1H21	YoY	2Q20	2Q21	YoY	1Q21	2Q21
Net profit attribute to shareholders	491	755	54.0%					
Insurance	622	1,029	65.4%					
Technology	(107)	(137)	28.7%					
Bank	(111)	(207)	85.5%					
Others	(55)	(84)	53.4%					
Revenue from Technology export	120	266	122.1%					
Combined ratio (%)	103.5	99.4	(4.1) ppt					
Expense ratio (%)	46.9	50.0	3.1 ppt					
Loss ratio (%)	56.6	49.4	(7.2) ppt					
Net investment yield (%)	1.9	1.2	(0.7) ppt					
Total investment yield (%)	3.6	3.4	(0.2) ppt					
Comprehensive investment yield (%)	7.7	4.9	(2.8) ppt					
Total investment assets	28,471	38,908	36.7%					
Total investment income	868	944	8.7%					
Premium income breakdown by ecosystems:								
Health	3,049	3,926	28.7%					
Digital lifestyle	2,197	3,345	52.3%					
Consumer finance	751	2,193	192.1%					
Auto	457	378	-17.4%					
Others	588	-	-100.0%					
Total	6,766	9,841	45.4%					
Loss ratio by ecosystems:								
Health	45.1	37.1	(8.0) ppt					
Digital lifestyle	62.7	62.1	(0.6) ppt					
Consumer finance	69.8	38.9	(30.9) ppt					
Auto	50.2	71.5	21.3 ppt					
Travel	7.2	-	(7.2) ppt					
Others	75.1	-	(75.1) ppt					
Channel fees as a percentage of net written								
premiums(%):	00.4	07.0	(0 E) ant					
Health	28.4	27.9	(0.5) ppt					
Digital lifestyle	30.1	35.4	5.3 ppt					
Consumer finance	9.4	16.2	6.8 ppt					
Auto	25.4	13.8	(11.6) ppt					
Travel	77.0	-	(77.0) ppt					
Others Source: Company data, CMBIS	17.0	-	(17.0) ppt					

Source: Company data, CMBIS

## **Financial Summary**

Income statement						Key ratios					
YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec	FY19A	FY20A	FY21E	FY22E	FY23E
Gross written premium	14,630	16,709	22,307	26,554	32,683	Growth (%)					
Net premiums earned	12,801	16,215	19,796	23,851	29,506	GWP growth	30.0%	14.2%	33.5%	19.0%	23.1%
Investment income	1,946	1,502	997	1,012	1,069	Total income growth	57.4%	22.3%	15.8%	19.9%	23.3%
Other operating income	377	776	620	817	1,084	Net profit growth	N/A	N/A	76.0%	21.5%	57.4%
Total income	15,124	18,493	21,413	25,680	31,658	Investment assets growth	7.5%	63.4%	-10.8%	14.0%	0.0%
Insurance claims	(8,625)	(8,774)	(9,660)	(11,668)	(14,553)	Investment yield (%)					
Handling charges & commissions	(910)	(1,407)	(1,374)	(1,487)	(1,746)	Net investment yield	4.8%	3.0%	2.7%	3.0%	2.9%
Other operating expenses	(6,156)	(8,132)	(9,944)	(11,997)	(14,527)	Total investment yield	9.3%	5.3%	3.0%	2.9%	2.9%
Total expenses	(15,691)	(18,313)	(20,978)	(25,151)	(30,826)						
						Underwriting (%)					
Associates and JVs	(44)	(34)	(40)	(40)	(40)	Expense ratio	45.9%	48.4%	50.9%	49.9%	49.3%
Pre-tax profit	(611)	147	435	528	832	Loss ratio	67.4%	54.1%	48.8%	48.9%	49.3%
						Combined ratio	113.3%	102.5%	99.7%	98.8%	98.6%
Income tax	(28)	108	13	16	25						
Less: Minority interests	185	299	527	641	1,009	Technology segment					
Net profit	(454)	554	975	1,185	1,866	Tech revenue (RMB mn)	293	429	564	761	1,028
						Tech revenue growth (0/)	101 /	16.0	01 E	25 0	25.0
Balance sheet						Tech net nrofit (RMR mn)	(334)	(368)	(347)	(226)	(44)
YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	Returns (%)					
Investment assets	18,993	31,026	27,666	31,540	31,540	ROA	-1.6%	1.4%	2.4%	3.7%	7.5%
other assets	6,513	8,320	6,714	(2,524)	(10,885)	ROE	-3.0%	3.6%	6.0%	6.8%	9.8%
Total assets	30,908	45,673	34,381	29,016	20,655						
						Solvency (%)					
Insurance liabilities	7,543	8,547	2,425	(6,383)	(18,145)	Core solvency ratio	502%	502%	487%	473%	459%
Other liabilities	6,859	19,733	13,282	15,309	16,542	Comprehensive solvency ratio	502%	502%	487%	473%	459%
Total liabilities	14,402	28,280	15,706	8,927	(1,602)						
						Per share (RMB)					
Shareholders' equity	14,912	15,705	16,862	18,139	20,097	EPS	(0.3)	0.4	0.7	0.8	1.3
Minority interest	1,594	1,688	1,812	1,950	2,160	DPS	0	0	0	0	0
Total equity	16,506	17,393	18,674	20,089	22,257	BVPS	11.2	11.8	12.7	13.7	15.1

Total equity 16,506 17, Source: Company data, CMBIS estimates





# **Disclosures & Disclaimers**

#### **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIS
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

#### CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

#### Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on a "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

#### For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investors that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

#### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.